Arena Pharmaceuticals, Inc. (ARNA)

[hlegweakreturns]

The presentation notes the real risks:
There are two limitations of use -- the drug has not been studied in combination. However, there are plans with a site to look at -- combination coming soon. And secondly, the effect of BELVIQ on cardiovascular morbidity and mortality has not been established. However there are plans for the cardiovascular outcome trial that Eisai will be running in the coming future. - See more at: http://www.earningsimpact.com/Transcript/83602/ARNA/Arena-Pharmaceuticals%2c-Inc----Bank-of-America-Merrill-Lynch-Global-Healthcare-Conference#sthash.ann5TF57.dpuf